Paris - Delayed Quote • EUR
Valbiotis SA (ALVAL.PA)
At close: April 26 at 5:35 PM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 4 | 4 |
| Avg. Estimate | 0 | 0 | -0.77 | -0.73 |
| Low Estimate | 0 | 0 | -1.28 | -0.93 |
| High Estimate | 0 | 0 | -0.5 | -0.3 |
| Year Ago EPS | -- | -- | -1.21 | -0.77 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 3 | 3 |
| Avg. Estimate | -- | -- | 5.73M | 10.43M |
| Low Estimate | -- | -- | 5.4M | 5M |
| High Estimate | -- | -- | 6M | 15.3M |
| Year Ago Sales | -- | -- | 2.81M | 5.73M |
| Sales Growth (year/est) | -- | -- | 103.60% | 82.00% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -0.77 | -0.73 |
| 7 Days Ago | 0 | 0 | -0.77 | -0.73 |
| 30 Days Ago | 0 | 0 | -0.77 | -0.73 |
| 60 Days Ago | 0 | 0 | -0.77 | -0.73 |
| 90 Days Ago | 0 | 0 | -0.84 | -0.73 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ALVAL.PA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 6.50% |
| Next Qtr. | -- | -- | -- | 12.00% |
| Current Year | 36.40% | -- | -- | 5.30% |
| Next Year | 5.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
ALINT.PA IntegraGen SA
0.5900
-1.67%
ADOC.PA Adocia SA
8.43
+4.46%
ALSEN.PA Sensorion SA
0.7060
-0.56%
ALCOX.PA Nicox S.A.
0.3740
-0.27%
OSE.PA OSE Immunotherapeutics SA
5.56
-0.71%
NANO.PA Nanobiotix S.A.
5.45
+0.93%
GLMD Galmed Pharmaceuticals Ltd.
0.3916
+0.90%
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%